Head-to-head · WeighScore
DrMedHealth vs Medi-Weightloss
By GLP-1 ScorecardUpdated
Score comparison
Medi-Weightloss has the higher recorded score — 69.6/100 to 60.8/100.
Medi-Weightloss grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Medi-Weightloss is an established physician-supervised weight-loss brand with 130-plus locations nationwide plus telehealth.
We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.
Factor by factor
These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.
The numbers
Swipe or scroll to compare both providers.
| Metric | DrMedHealth | Medi-Weightloss |
|---|---|---|
| WeighScore | 60.8/100 | 69.6/100 |
| Grade | C | C |
| Site position | #355 | #134 |
| Semaglutide | $199/mo (starting dose, compounded) | $199/mo (promotional rate, brand-name) |
| Tirzepatide | $299/mo (starting dose, compounded) | Not disclosed |
| Coverage | Coverage not published | Coverage not published |
| Brand-name access | Yes | Yes |
| Oral / sublingual | Not confirmed | Not confirmed |
Site position #355 · C
FDAWarning letter issued to Public Health Solution LLC dba DrMedHealth in June 2026. See the FDA warning-letter database.
Strengths
- LegitScript certified telehealth platform
- Low compounded pricing: semaglutide from $199/mo, tirzepatide from $299/mo
- Both compounded and FDA-approved branded options available
- Fast physician review (advertised ~2 hours) with free shipping
- Compounded by licensed US pharmacies
What to consider
- Compounded GLP-1s are not FDA-approved for safety, efficacy or quality
- Cash-pay model; insurance generally not accepted for medication
- Full list of available states not consolidated in one place
- Site is JavaScript-rendered, limiting easy review of full terms
- FDA issued Public Health Solution LLC dba DrMedHealth a warning letter in June 2026; the letter is public in FDA's warning-letter database
Site position #134 · C
Strengths
- Both branded (Wegovy, Zepbound) and compounded semaglutide/tirzepatide
- Established brand with 130+ physician-supervised locations nationwide
- Telehealth plus in-person clinic options
- Accepts insurance at many locations; HSA/FSA welcome
- Includes body-composition analysis and personalized plans
What to consider
- Ongoing medication pricing not transparently posted; varies by plan
- $199 new-patient visit fee before medication costs
- Frequent (often weekly) visits expected for some patients
- Compounded products are not FDA-approved or evaluated
Featured provider
CoreAge Rx
CoreAge Rx scores 89.5/100 (B+). Advertises pricing across doses with no membership fee, but starting-price displays and FAQ payment/refund promises need to be reconciled with the selected plan and refund policy.
Commercial relationships affect this placement. The score comparison above is separate.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.